{"prompt": "['testing), clinically significant electrolyte abnormalities (e.g., hypokalaemia, hypomagnesemia,', 'hypocalcaemia), or family history of sudden unexplained death or long QT syndrome', 'Inadequate bone marrow function, defined by any of:', '-', 'Absolute neutrophil count < 1.5 X 10%/L', '-', 'Platelet count < 100 X 10%/L', '-', 'Haemoglobin < 9 g/dL', 'Impaired liver function, defined by any of:', '-', \"Serum (total) bilirubin > 1.25 X upper limit of normal (ULN). In case of Gilbert's syndrome: a\", 'total bilirubin of 2 X ULN is permitted.', '-', 'Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 1.25 X ULN', '-', 'Albumin < 25 g/L', 'Inadequate renal function with serum creatinine > 1.5 X ULN', 'Current severe, uncontrolled systemic disease that may interfere with planned treatment (e.g.,', 'clinically significant cardiovascular, pulmonary, or metabolic disease; wound-healing disorders)', 'Pregnant or breastfeeding, or intending to become pregnant during the study or within seven', 'months after the last dose of study treatment. Women of childbearing potential must have a', 'negative serum pregnancy test result within seven days prior to initiation of study treatment', \"Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's\", \"judgment, precludes the patient's safe participation in, and completion of, the study\", 'Known active liver disease, for example, active viral hepatitis infection (i.e., hepatitis B or hepatitis', 'C), autoimmune hepatic disorders, or sclerosing cholangitis', 'Concurrent, serious, uncontrolled infections, or known infection with human immunodeficiency', 'virus (HIV)', 'Known hypersensitivity to any of the study drugs, excipients, and/or murine proteins', 'Current chronic daily treatment with corticosteroids (dose > 10 mg methylprednisolone or', 'equivalent excluding inhaled steroids)', 'End of Study', 'The end of the study is defined the Last Patient, Last Visit (LPLV) which will occur three years after', 'the last patient is randomized or the date at which the last data point required for the final statistical', 'analysis or safety follow-up is received from the last patient, whichever occurs later.', 'In addition, the Sponsor may decide to terminate the study at any time.', 'Length of Study', 'The study is estimated to last approximately 4 years, based on a recruitment period of up to 10', 'months and 3 years of follow-up after the last patient is randomized.', 'Investigational Medicinal Products', 'The investigational medicinal products (IMPs) for this study are pertuzumab and trastuzumab FDC', 'SC, Perjeta IV, and Herceptin IV.', 'Test Product (Investigational Drug)', 'Pertuzumab and trastuzumab FDC SC is given as a fixed dose (i.e. non-weight based). Pertuzumab', 'and trastuzumab FDC SC will be provided in a loading dose configuration and a maintenance dose', 'configuration. The 15 mL loading dose consists of 1200 mg pertuzumab and 600 mg trastuzumab.', 'The 10 mL maintenance dose consists of 600 mg pertuzumab and 600 mg trastuzumab. Patients who', 'have had 6 weeks since their last neoadjuvant dose of Perjeta or Herceptin at study entry, or have', 'had 6 weeks since their last study treatment during the study treatment periods, must receive a', 'loading dose before continuing with maintenance doses for subsequent administrations. All', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '23 / Protocol MO40628, Version 12']['pertuzumab and trastuzumab FDC SC doses are administered by SC injection over 5 - 8 minutes at a', 'rate of 2 mL/min with hand-held syringe to the thigh on Day 1 of each 3-week treatment cycle.', 'Patients should be monitored for 30 minutes after their first pertuzumab and trastuzumab FDC SC', 'dose administration regardless of whether a loading dose is required. Patients should be monitored', 'for 10 - 15 minutes following subsequent administrations. Patients can be observed for longer periods', 'at the discretion of the investigator or if necessary, as per local requirements.', 'Comparator (Active Control)', 'Perjeta IV is administered at a dose of 840 mg (loading dose) or 420 mg (maintenance dose) on Day', '1 of each 3-week treatment cycle and should be administered before Herceptin IV. Patients who have', 'had 6 weeks since their last neoadjuvant dose of Perjeta at study entry, or have had 6 weeks', 'since their last study treatment during the study treatment periods, must receive a loading dose', 'before continuing with maintenance doses for subsequent administrations. Perjeta IV loading dose (if', 'required) will be administered as a 60-minute infusion ( 10 minutes), followed by an observation', 'period of 60 minutes. If the loading dose infusion is well tolerated, subsequent maintenance doses', 'can be administered over a period of 30 minutes ( 10 minutes) with an observation period of 30', 'minutes. Patients can be observed for longer periods at the discretion of the investigator or if', 'necessary, as per local requirements. The observation period should be completed prior to the', 'subsequent Herceptin IV infusion.', 'Herceptin IV is administered at a dose of 8 mg/kg (loading dose) or 6 mg/kg (maintenance dose) on', 'Day 1 of each 3-week treatment cycle. Patients who have had 6 weeks since their last neoadjuvant', 'dose of Herceptin at study entry, or have had 6 weeks since their last study treatment during the', 'study treatment periods, must receive a loading dose before continuing with maintenance doses for', 'subsequent administrations. Herceptin IV loading dose (if required) will be administered as an infusion', 'over approximately 90 ( 10) minutes after which the patient must be observed for 60 minutes. If the', 'loading dose is well tolerated, subsequent maintenance doses can be administered as 30-minute', 'infusions ( 10 minutes) followed by an observation period of 30 minutes. Patients can be observed', 'for longer periods at the discretion of the investigator or if necessary, as per local requirements.', 'Non-Investigational Medicinal Products', 'Not applicable.', 'Statistical Methods', 'Primary Analysis', 'The primary objective of this study is to evaluate patient preference for pertuzumab and trastuzumab', 'FDC SC based on the proportion of patients indicating an overall preference for pertuzumab and', 'trastuzumab FDC SC based on Question 1 of the PPQ. Question 1 of the PPQ is as follows: \"All', 'things considered, which method of administration did you prefer?\".', 'The primary endpoint will be analysed for the intent-to-treat (ITT) population and for the modified ITT', '(mITT) population. The mITT population will include all patients who received at least one dose by', 'both SC and IV routes of administration during the Treatment Cross-over Period and subsequently', 'answered at least Question 1 of the PPQ.', 'A point estimate with associated 95% confidence interval (CI) for the proportion of patients who', 'preferred pertuzumab and trastuzumab FDC SC will be calculated for the mITT and ITT populations.', 'Analysis of the primary study endpoint will take place when all patients have completed their last', 'treatment administration during the Treatment Cross-over Period.', 'Determination of Sample Size', 'The binary primary endpoint (the proportion of patients who express a preference for pertuzumab and', 'trastuzumab FDC SC) will be estimated with associated two-sided 95% Cl.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '24 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}